Oxidative stress and uremia

Medicinal Research Reviews

Volumn 25, Issue 4, 2005, Pages 473-486

  Floccari, Falvio ^a   Aloisi, Carmela ^a,b   Crascí, Eleonora ^a   Sofi, Tito ^a   Campo, Susanna ^a   Tripodo, Donatella ^a   Criseo, Manila ^a   Frisina, Nicola ^a   Buemi, Michele ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Nephrology ^*

Author keywords

AGE; AOPP; Hemodialysis; Kidney Transplant; Oxidative stress; Uremia

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXOTHIAZOLIDIN 5 ACETANILIDE; ACETANILIDE DERIVATIVE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALCOHOL; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; CARBOHYDRATE; CARBONYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRAZINE DERIVATIVE; LIPID; NUCLEIC ACID; RESIN; UNCLASSIFIED DRUG;

CELL ACTIVATION; DRUG INHIBITION; GLYCATION; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; LYMPHOCYTOPENIA; MONOCYTE; NEUTROPHIL; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; REVIEW; UREMIA;

EID: 21944438875     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20028     Document Type: Review

References (117)

1. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial 2001;14:193-199.
2. Kalantar-Zadeh K, Ikizler A, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 2003;42:864-881.
3. Newman Dorland W, Anderson D. Dorland's Illustrated Medical Dictionary. Philadelphia, PA: Saunders; 2000.
4. Witko-Sarsat V, Rieu P, Descamps-Latscha B. Neutrophils: Molecules, functions and pathophysiological aspects. Lab Invest 2000;80:617-653.
5. Jacobs AA, Jr., Ward RA, Wellhausen SR, McLeish KR. Polymorphonuclear leukocyte function during hemodialysis: Relationship to complement activation. Nephron 1989;52:119-124.
6. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
7. Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end stage renal disease. Kidney Int 1997;51:1170-1181.
8. Witko-Sarsat V, Friedlander M, Capeiller-Blandin C, et al. Advanced oxidized protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
9. Roselaar SE, Nahzat NB, Winyard PG, et al. Detection of oxidant in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995;48:199-206.
10. Sies H. Oxidative stress: Introductory remarks. In: Sies H, editor. Oxidative stress. Orlando: Academic Press; 1985. 1p.
11. Diaz MN, Frei B, Vita JA, et al. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337: 408.
12. Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. CREED investigators. Cardiovascular risk extended evaluation in dialysis patients. J Hypertens 2000;18:1207-1213.
13. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
14. Heinecke JW. Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 1996;7:U131-U136.
15. Miyata T, Kurokawa K, van Ypersele de Strihou C, et al. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000;58:120-125.
16. Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990;1:150-160.
17. Odetti P, Garibaldi S, Gurreri G, et al. Protein oxidation in hemodialysis and kidney transplantation. Metabolism 1996;45:1319-1322.
18. Zhang Z, Dmitrieva N, Park JH, et al. High urea and NaCl carbonylate proteins in renal cells in culture and in vivo, and high urea causes 8-oxoguanine lesions in their DNA. Proc Natl Acad Sci 2004;22:9491-9496.
19. Singer SJ, Nicholson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175:720.
20. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: Markers and management. J Nephrol 2002;15:336-341.
21. Giray B, Kan E, Bali M, et al. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta 2003;338:91-98.
22. Holvoet P, Perez G, Zhian Z, et al. Malondialdehyde-modified LDL in patients with atherosclerotic disease. J Clin Invest 1995;95:2611.
23. Yeo HC, Helbock HJ, Chyu DW, et al. Assay of malonyldialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 1994;220:391-396.
24. Ozden M, Maral H, Akaydin D, et al. Erythrocyte glutathione peroxidase activity, plasma malonildialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002;35:269-273.
25. Daschner M, Lenhartz H, Botticher D, et al. Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996;50:1268-1272.
26. Canestrari F, Buoncristiani U, Galli F, et al. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 1995;234: 127-136.
27. Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in hemodialysis. QJM 1994;87:679-683.
28. Paul JL, Sail ND, Soni T, Poignet JL, et al. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron 1993;64:106-109.
29. Gotoh M, Nagase S, Aoyagi K, Hirayama A, Takemura K, Ueda A, Tomida C, Kikuchi H, Koyama A. Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. Nephrol Dial Transpl 1997;12:713-717.
30. Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991;57:10-15.
31. Pratico D, Lawson JA, Rokach J, et al. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001;12:243-247.
32. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2 isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59:1960-1966.
33. Maggi E, Bellazzi R, Gazo A, et al. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
34. Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Tromb Haemost 1996;76:663-669.
35. Davies KJ. Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 1987; 262:9895-9901.
36. Wratten ML, Sereni L, Tetta C. Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins. Artif Organs 2000;24:685-690.
37. Witko-Sarsat V, Friedlander M, Capeiller-Blandin C, et al. Advanced oxidized protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
38. Witko-Sarsat V, Gausson V, Descamps-Latscha X. Are advanced oxidation products potential uremic toxins? Kidney Int 2003;63:S11-S14.
39. Kalousova M, Zima T, Tesar V, et al. Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int 2003;63:S62-S64.
40. Gorge J, Afek A, Gilburd B, et al. Autoimmunity in atherosclerosis: Lessons from experimental models. Lupus 2000;9:223-227.
41. Kaneda H, Taguchi J, Ogasawara K, et al. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221-225.
42. Sebekova K, Podracka L, Heidland A. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammmatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement by dialysis and transplantation- are they inter-related? Clin Nephrol 2001;56:S21-S26.
43. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. Immunoichemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 1992;267:10211-10214.
44. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;267:2463-2469.
45. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;41:153-159.
46. Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992;41:36-41.
47. Miyata T, Inagi R, Asahi K, et al. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acid. FEBS Lett 1998; 437:24-28.
48. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractioned bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-270.
49. Miyata T, Ueda Y, Shinzato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end stage renal failure. Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-1206.
50. Thornalley PJ. Advanced glycation and development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 1996;3:149-166.
51. Henle T, Miyata T. Advanced glycation end product in uremia. Adv Ren Rep Ther 2003;10:321-331.
52. Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, and advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
53. Vlassara H. Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54-59.
54. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001;15: 203-210.
55. Meng J, Sakata N, Imanaga Y, et al. Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure. Clin Nephrol 1999;51:280-289.
56. Miyata T, Kurokawa K, van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000;11:1174-1752.
57. Wolff SP Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339-352.
58. Ueda Y, Miyata T, Hashimoto T, et al. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. Biochem Biophys Res Commun 1998;245:785-790.
59. Anderson MM, Requena JR, Crowley JR, et al. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-113.
60. Schmidt AM, Vianna M, Gerlach J, et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992;267:14987-14997.
61. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
62. Miyata T, Jadoul M, Kurokawa K, et al. β2-microglobulin in renal disease. J Am Soc Nephrol 1998;9: 1723-1735.
63. Miyata T, Hori O, Zhang JH, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-b 2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest 1996;98:1088-1094.
64. Zeier M, Schwenger V, Deppisch R. Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
65. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW. Serum advanced glycosylation end-products in patients on hemodialysis and CAPD. Perit Dial Int 1995;15:129-133.
66. Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425-435.
67. Imani F, Horii Y, Suthanthiran M, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of Interferon gamma: Role in tissue remodelling. J Exp Med 1993;178:2165.
68. Henle T, Deppisch R, Ritz E, et al. The Maillard reaction: From food chemistry to uremia research. Nephrol Dial Transpl 1996;11:1719-1722.
69. Faist V, Erbersdobler HF Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 2001;45:1-12.
70. Henle T. AGE in foods: Do they play a role in uremia? Kidney Int 2003;63:145-147.
71. Schwedleer BS, Metger T, Schinzel R, et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-310.
72. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, Van Ypersele De Strihou C, Miyata T. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". Kidney Int 1999;55:2487-2492.
73. Durak I, Ayol O, Basesme E, et al. Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 1994;66:76-80.
74. Canestrari F, Galli F, Giorgini A, et al. Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994;91:187-193.
75. Canaud B, Cristol J, Morena M, et al. Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purif 1999;17:99-106.
76. Miyata T, van Ypersele de Strihou C, Imasawa T, et al. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products. Kidney Int 2001;60:2351-2359.
77. Miyata T, Ueda Y, Asahi K, et al. Mechanism of the inhibitory effect of OPB-9195 [(±)2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced lipoxidation end product formation. J Am Soc Nephrol 2000;11:1719-1725.
78. Ahkand AA, Kato M, Suzuki H, et al. Carbonyl compounds cross link cellular proteins and activate protein-tyrosine kinase p60-src. J Cell Biochem 1999;72:1-7.
79. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 1991;40:1328-1334.
80. Miyata T, Ishikawa S, Asahi K, et al. 2-Isopropylidenehydrazono-4-oxo- thiazolidin-5ylacetanilide (OPB-9195) inhibits the neointima proliferation of rat carotid artery following balloon injury: Role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 1999;445:202-206.
81. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 18; 343:1519-1522.
82. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensine II receptor antagonists and angiotensin convertin enzyme (ACE) inhibitors scavenge oxidative radicals and lower the formation of advanced glycation end products. J Am Soc Nephrol 2002;13:2478-2487.
83. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advance glycation endproducts. Nat Med 1998;4:1025.
84. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003;419:80-88.
85. Jerums G, Panagiotopoulos S, Forbes J. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 2003;419:55-62.
86. Vasan S, Zhang X, Zhang X, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275.
87. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630.
88. Schwedler SB, Verbeke P, Bakala H, Weiss MF, Vilar J, Depreux P, Fourmaintraux E, Striker LJ, Striker GE. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice. Diabetes Obes Metab 2001;3:230-239.
89. Inagi R, Miyata T, Ueda Y, et al. Efficient detoxification of carbonyl stress by the glyoxalase system in peritoneal dialysis. Kidney Int 2002;62:679-687.
90. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, Descamps-Latscha B. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003;64:82-91.
91. Giray B, Kan E, Bali M, et al. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta 2003;338:91-98.
92. Dieber-Rotheneder M, Puhl H, Waeg G, et al. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low-density lipoproteins and resistance to oxidation. J Lipid Res 1991;32: 1325.
93. Princen HMG, Van Poppel G, Vogelezang C, et al. Supplementation with vitamin E but not beta carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Arterioscl Thromb 1992;12:554.
94. Reaven P, Khouw A, Beltz W, et al. Effect of dietary antioxidant combinations in humans: Protection of low density lipoprotein by vitamin E not beta carotene. Arterioscl Thromb 1992;12:554.
95. Pincen HMG, van Duyvenvoorde W, Buytenhek R, et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscl Thromb Vasc Biol 1995;15:323.
96. Jialal I, Fuller CJ, Beverley AH. The effect of alpha-tocopherol supplementation on LDL oxidation: A dose response study. Arterioscler Thromb Vasc Biol 1995;15:190.
97. Jilial I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit oxidative modification of low density lipoprotein. Atherosclerosis 1990;82:185.
98. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr 1991;54:1113S.
99. Karats D, Chevion S, Nahir M, et al. Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: Presumptive evidence for an interaction between vitamins C and E in vivo. Am J Clin Nutr 1998;67:240.
100. Karats D, Ben-Nairn M, Dabach Y, et al. Effect of vitamin C and E on susceptibility of plasma lipoproteins to peroxidations induced by acute smoking. Atherosclerosis 1990;85:47.
101. Herbert V, Shaw S, Jayatilleke E. Vitamin C supplements are harmful to lethal for over 10% of Americans j with high iron stores. FASEB J 1994;8:A678.
102. Podmore ID, Griffiths HR, Herbert KE, et al. Vitamin C exhibits pro-oxidant properties. Nature 1998; 392:559.
103. Al-Abed Y, Mitsuhashi T, Li H, et al. Inhibition of advanced glycation and product formation by acetaldehyde: Role in the cardioprotective effect of ethanol. Proc Natl Acad Sci USA 1999;96:2385.
104. Ishikawa N, Miyata T, Ueda Y, et al. Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 2003;63:331-339.
105. Pernice F, Floccari F, Caccamo C, Belghity N, Mantuano S, Pacilè ME, Romeo A, Barillà A, Aloisi C, Ruello A, Frisina N, Buemi M. Oxidative stress, sister chromatid exchanges and apoptosis in the pathogenesis of lymphocytopenia in ESRD patients. Blood Purif (in press).
106. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25:445-451.
107. Vlassara H. Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54-59.
108. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003;42:524-531.
109. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Kirk R, Cerami A, Vlassara H. Reactive glycosylation end products in diabetic uremia and treatment of renal failure. Lancet 1994;343:1519-1522.
110. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C. Related articles, accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
111. Trang DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH. Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000;58:790-799.
112. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 1999;71:S126-S129.
113. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer. Circulation 2000;101: 1002-1006.
114. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887.
115. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, Buoncristiani E, Floridi A. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003;64: 748-755.
116. Van Tellingen A, Grooterman MP, Bartels PC, et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in haemodialysis patients. Kidney Int 2001;59:342-347.
117. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD. Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 1995;10:103-107.